Anticoagulants-
Patients who are using medications that can prolong bleeding (eg aspirin, warfarin) may
as with any injection, experience increased bruising or bleeding at the injection site

Facial fat loss ( lipotrophy )

                                 Mild         Moderate   Severe
                                   %                   %             %
Dermatologic-    

    Ecchymosis          50               38               7
    Erythema              57                41              0
    Pruritus                 84                14               0

Miscellaneous   

    Edema                 45                 48              4
    Pain                      63                 34              0
    Other                    61                  34             2

Other adverse reactions include-  contour irregularities, burning sensation,
numbness, whiteheads

Allergies manifested as anaphylaxis

Special Precautions-

Inflammation/infection- use of calcium hydroxylapitite  in any person with active skin inflammation
or infection in any or near treated area should be deferred  until infectious process has been
controlled

Local reactions- injection procedure reactions observed consisted mainly of short term-
nature less than 7 days  (eg. swelling, redness, bruising )

Administration- take special care to avoid injection into blood  vessels. An introduction into
vasculature may occlude the vessels and could cause infarction or embolism

Use in lips- the safety and effectiveness of calcium hydroxylapitite for use in lips have not been
established.

Long term use- long term safety and effectiveness of calcium hydroxlapitite  beyond 1 year
have not been established

Keloid formation /hypertrophic scarring-  safety of calcium hydroxylapitite in patients with
increased susceptibiity to keloid formation and hypertrohic scarring has not been established

Periorbital areas-  safety and effectiveness of calcium hydroxylaptite in perorbital area have not
been established.

Photosensitivity - inform the patient he or she should minimize exposure of the treated area to
extensive sun heat exposure for approximately 24 hours after treatment or until swelling and
redness have resolved.

Pregnancy- safety for use during pregnancy has not been established

Lactation- safety for use in breast feeding mothers has not been established

Children- safety for use in patients younger than 18 years has not been established

Indication-
Facial fat loss ( lipotrophy )

Dosage-
Individualization of treatment- before treatment the patients suitability for treatment and need
for pain relief should be acessed.

The outcome of treatment with calcium hydroxylapitite will vary among patients .
In some instances, additional treatment may be necesary depending on the size of  the defect
and the needs of the patient

1. Inform patients to minimise exposure of the treated area to extensive sun or heat exposure
   for approximately 24 hours after treatment or until any initial swelling and redness have
   resolved.

Pregnancy-
Safety for use during pregnancy has not been established

Lactation-
Safety for use in breast feeding mothers has not been established

Children-
Safety for use in patients younger than 18 years has not been established